SCHEMBL11029902

SCHEMBL11029902

CC(c1cccc(F)c1)c1cnc(C(N)=O)c(Nc2ccc(N3CCN(C)CC3)c(Cl)c2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 5/20 0.44
▸ SLC2A1 P11166 2/20 0.44
▸ NPC1 O15118 5/20 0.42
▸ RAB9A P51151 4/20 0.42
▸ JAK3 P52333 2/20 0.42
▸ IKBKB O14920 1/20 0.42
▸ NPY2R P49146 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ RELA Q04206 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ WDR5 P61964 1/20 0.40
▸ CDK4 P11802 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11028698 0.89 CDK4 (0.51) CSF1RSLC2A1JAK3CDK4CCND1
SCHEMBL11029792 0.80 CCNA2 (0.50) JAK3CDK4CCND1
SCHEMBL11033513 0.79 CSF1R (0.44) CSF1RSLC2A1NPC1RAB9AJAK3
SCHEMBL11033999 0.79 SLC2A1 (0.51) CSF1RSLC2A1CDK4CCND1
SCHEMBL11032168 0.78 NPC1 (0.50) CSF1RSLC2A1NPC1RAB9AJAK3
SCHEMBL11026741 0.75 FYN (0.55) CSF1RSLC2A1CDK4CCND1
SCHEMBL11028029 0.71 CDK4 (0.53) CSF1RSLC2A1JAK3CDK4CCND1
SCHEMBL11030745 0.71 CDK4 (0.50) CSF1RSLC2A1JAK3MEN1KMT2A
SCHEMBL11031519 0.70 SLC2A1 (0.57) CSF1RSLC2A1JAK3CDK4CCND1
SCHEMBL11027433 0.70 MAPKAPK2 (0.60) CSF1RSLC2A1JAK3CDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP claimed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 CSF1R 3377/4885SLC2A1 3662/4885NPC1 1733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback